The general purpose of the Neomindset trial is to evaluate the non-inferiority hypothesis for
ischemic events and the superiority hypothesis for bleeding events resulting from platelet
P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual
antiplatelet therapy in acute coronary syndrome patients treated with percutaneous coronary
intervention.
The platelet sub-study will be conducted at the Hospital Israelita Albert Einstein. This
sub-study will recruit randomized patients from the Neomindset trial to evaluate platelet
function after at least 30 days of study treatment with either P2Y12 inhibitor monotherapy or
dual antiplatelet therapy.